Innogenetics Preps New 4-MAT Assays for CE Mark as It Considers GenProbe, Solvay Bids | GenomeWeb
Belgian biotechnology company Innogenetics may be in a “season of bidding,” but it is moving forward with plans to introduce two new microarray-based assays that will complement a human leukocyte antigen-testing service the company introduced earlier this year.
Filip Goossens, Innogenetics’ head of investor relations, told BioArray News this week that the company expects to obtain CE Marks for its HLA-B and HLA-DRB1 assays by the end of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.